# A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

> **NCT03381066** · PHASE3 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 225 (estimated)

## Conditions studied

- Completely Resected NSCLC With Common EGFR Mutations

## Interventions

- **DRUG:** gefitinib, pemetrexed,cisplatin
- **DRUG:** Vinorelbine, cisplatin

## Key facts

- **NCT ID:** NCT03381066
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-10
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381066, "A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03381066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*